Edwin Jousma

867 total citations
8 papers, 611 citations indexed

About

Edwin Jousma is a scholar working on Neurology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Edwin Jousma has authored 8 papers receiving a total of 611 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Neurology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Genetics. Recurrent topics in Edwin Jousma's work include Neurofibromatosis and Schwannoma Cases (8 papers), Neuroblastoma Research and Treatments (5 papers) and Sarcoma Diagnosis and Treatment (4 papers). Edwin Jousma is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (8 papers), Neuroblastoma Research and Treatments (5 papers) and Sarcoma Diagnosis and Treatment (4 papers). Edwin Jousma collaborates with scholars based in United States and Mali. Edwin Jousma's co-authors include Nancy Ratner, Jianqiang Wu, Eva Dombi, Mi‐Ok Kim, Tilat A. Rizvi, Timothy P. Cripe, David Eaves, R. Scott Dunn, Brigitte C. Widemann and José A. Cancelas and has published in prestigious journals such as Journal of Clinical Investigation, Cancer Research and Oncogene.

In The Last Decade

Edwin Jousma

8 papers receiving 608 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edwin Jousma United States 7 431 218 163 79 73 8 611
Mary Jo Wenning United States 8 390 0.9× 131 0.6× 182 1.1× 70 0.9× 82 1.1× 9 581
Tanya Basu United Kingdom 7 380 0.9× 134 0.6× 191 1.2× 88 1.1× 159 2.2× 18 686
Heli Ylä‐Outinen Finland 13 372 0.9× 165 0.8× 121 0.7× 37 0.5× 87 1.2× 22 660
Silke Frahm Germany 8 431 1.0× 197 0.9× 128 0.8× 40 0.5× 82 1.1× 8 534
Ali Fuat Okuducu Germany 12 135 0.3× 127 0.6× 161 1.0× 91 1.2× 64 0.9× 19 426
Eva Pros Spain 14 133 0.3× 160 0.7× 372 2.3× 159 2.0× 58 0.8× 19 619
Manfred Westphal Germany 7 204 0.5× 104 0.5× 303 1.9× 124 1.6× 152 2.1× 11 752
Anita Olofsson Sweden 10 152 0.4× 184 0.8× 382 2.3× 61 0.8× 16 0.2× 10 615
F. Vega France 10 387 0.9× 60 0.3× 158 1.0× 80 1.0× 53 0.7× 14 616
John‐Paul Kilday United Kingdom 18 313 0.7× 138 0.6× 344 2.1× 98 1.2× 219 3.0× 34 855

Countries citing papers authored by Edwin Jousma

Since Specialization
Citations

This map shows the geographic impact of Edwin Jousma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edwin Jousma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edwin Jousma more than expected).

Fields of papers citing papers by Edwin Jousma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edwin Jousma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edwin Jousma. The network helps show where Edwin Jousma may publish in the future.

Co-authorship network of co-authors of Edwin Jousma

This figure shows the co-authorship network connecting the top 25 collaborators of Edwin Jousma. A scholar is included among the top collaborators of Edwin Jousma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edwin Jousma. Edwin Jousma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Choi, Kwangmin, Edwin Jousma, Tilat A. Rizvi, et al.. (2018). STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma. Oncogene. 38(15). 2876–2884. 44 indexed citations
2.
Choi, Kwangmin, Kakajan Komurov, Edwin Jousma, et al.. (2017). An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. Scientific Reports. 7(1). 43315–43315. 38 indexed citations
3.
Jousma, Edwin, Tilat A. Rizvi, Jianqiang Wu, et al.. (2015). Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. Pediatric Blood & Cancer. 62(10). 1709–1716. 53 indexed citations
4.
Wu, Jianqiang, Deanna M. Patmore, Edwin Jousma, et al.. (2013). EGFR–STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene. 33(2). 173–180. 75 indexed citations
5.
Prada, Carlos E., Edwin Jousma, Tilat A. Rizvi, et al.. (2012). Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathologica. 125(1). 159–168. 109 indexed citations
6.
Jessen, Walter J., Shyra J. Miller, Edwin Jousma, et al.. (2012). MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. Journal of Clinical Investigation. 123(1). 340–347. 242 indexed citations
7.
Wu, Jianqiang, Vincent W. Keng, Deanna M. Patmore, et al.. (2012). Abstract 2937: An EGFR-STAT3 pathway promotes NF1 peripheral nerve tumorigenesis and transformation. Cancer Research. 72(8_Supplement). 2937–2937. 2 indexed citations
8.
Wu, Jianqiang, Eva Dombi, Edwin Jousma, et al.. (2011). Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatric Blood & Cancer. 58(2). 173–180. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026